300142 沃森生物
已收盘 07-30 15:00:00
资讯
新帖
简况
沃森生物:拓宽中长期直接融资渠道
证券之星 · 07-28 15:57
沃森生物:拓宽中长期直接融资渠道
沃森生物:2026年度向特定对象发行A股股票按计划推进
证券之星 · 07-28 11:38
沃森生物:2026年度向特定对象发行A股股票按计划推进
7月24日沃森生物跌9.95%,招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 07-24
7月24日沃森生物跌9.95%,招商国证生物医药指数(LOF)C基金重仓该股
沃森生物(300142)披露召开2026年第三次临时股东会通知,7月23日股价下跌1.7%
证券之星 · 07-23
沃森生物(300142)披露召开2026年第三次临时股东会通知,7月23日股价下跌1.7%
沃森生物最新公告:子公司双价HPV疫苗获坦桑尼亚药品注册证书
证券之星 · 07-23
沃森生物最新公告:子公司双价HPV疫苗获坦桑尼亚药品注册证书
沃森生物:公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中
证券之星 · 07-23
沃森生物:公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中
沃森生物:公司目前经营情况正常
证券之星 · 07-23
沃森生物:公司目前经营情况正常
沃森生物:截至4月底已收回玉溪沃森全部股权
证券之星 · 07-21
沃森生物:截至4月底已收回玉溪沃森全部股权
沃森生物:持续推进新冠变异株mRNA疫苗研发
证券之星 · 07-21
沃森生物:持续推进新冠变异株mRNA疫苗研发
公司问答丨沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段
格隆汇 · 07-20
公司问答丨沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段
沃森生物:爱森泽生物技术(昆明)有限公司作为公司光生物合成技术与产业化的平台
证券之星 · 07-20
沃森生物:爱森泽生物技术(昆明)有限公司作为公司光生物合成技术与产业化的平台
沃森生物:2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中
证券之星 · 07-20
沃森生物:2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中
沃森生物:公司严格按照《企业会计准则》及公司具体会计政策界定疫苗研发支出的资本化与费用化时点
证券之星 · 07-20
沃森生物:公司严格按照《企业会计准则》及公司具体会计政策界定疫苗研发支出的资本化与费用化时点
沃森生物:冻干带状疱疹mRNA疫苗于2025年12月获得《药物临床试验批准通知书》
证券之星 · 07-16
沃森生物:冻干带状疱疹mRNA疫苗于2025年12月获得《药物临床试验批准通知书》
沃森生物:九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 07-15
沃森生物:九价HPV疫苗目前处于III期临床研究阶段
沃森生物:2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中
证券之星 · 07-10
沃森生物:2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中
沃森生物:爱森泽生物聚焦医药健康天然产物的光生物合成
证券之星 · 07-10
沃森生物:爱森泽生物聚焦医药健康天然产物的光生物合成
沃森生物:公司严格遵守相关法律法规,不存在违规行为
证券之星 · 07-10
沃森生物:公司严格遵守相关法律法规,不存在违规行为
沃森生物:共有8个疫苗产品正式上市销售
证券之星 · 07-10
沃森生物:共有8个疫苗产品正式上市销售
股市必读:沃森生物(300142)7月3日董秘有最新回复
证券之星 · 07-06
股市必读:沃森生物(300142)7月3日董秘有最新回复
加载更多
公司概况
公司名称:
云南沃森生物技术股份有限公司
所属行业:
医药制造业
上市日期:
2010-11-12
主营业务:
云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业,也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。
发行价格:
95.00
{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"沃森生物","latestPrice":12.18,"timestamp":1785395022000,"preClose":12.19,"halted":0,"volume":52371159,"delay":0,"changeRate":-0.0008,"floatShares":1577000000,"shares":1599000000,"eps":0.1787,"marketStatus":"已收盘","change":-0.01,"latestTime":"07-30 15:00:00","open":12.07,"high":12.37,"low":11.95,"amount":636000000,"amplitude":0.0345,"askPrice":12.18,"askSize":35,"bidPrice":12.17,"bidSize":289,"shortable":0,"etf":0,"ttmEps":0.1787,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785461400000},"marketStatusCode":5,"adr":0,"adjPreClose":12.19,"symbolType":"stock","openAndCloseTimeList":[[1785375000000,1785382200000],[1785387600000,1785394800000]],"highLimit":13.41,"lowLimit":10.97,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":2.63,"roa":"--","peRate":68.158926,"roe":"1.41%","epsLYR":0.1111,"committee":-0.414918,"marketValue":19480000000,"turnoverRate":0.0332,"status":1,"floatMarketCap":19207000000},"requestUrl":"/m/hq/s/300142/","defaultTab":"news","newsList":[{"id":"2654074167","title":"沃森生物:拓宽中长期直接融资渠道","url":"https://stock-news.laohu8.com/highlight/detail?id=2654074167","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654074167?lang=zh_cn&edition=full","pubTime":"2026-07-28 15:57","pubTimestamp":1785225425,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月28日在投资者关系平台上答复投资者关心的问题。公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中,本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施,关于项目的相关信息请以公司披露的公告为准,请持续关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800022861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0239","BK0070","BK0077","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654020956","title":"沃森生物:2026年度向特定对象发行A股股票按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2654020956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654020956?lang=zh_cn&edition=full","pubTime":"2026-07-28 11:38","pubTimestamp":1785209896,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月27日在投资者关系平台上答复投资者关心的问题。现在证监会已经不允许固定价格定增了,当初设定9.6的定增价格是否正常沃森生物回复:尊敬的投资者,您好!公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中。本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800015979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0070","399300","159982","BK0077","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700911","title":"7月24日沃森生物跌9.95%,招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653700911?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:51","pubTimestamp":1784883068,"startTime":"0","endTime":"0","summary":"重仓沃森生物的前十大公募基金请见下表:根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共14家,其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元,最新净值0.3974,较上一交易日下跌0.5%,近一年下跌3.29%。招商国证生物医药指数C的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","161726","300142","BK0070","399441","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653268057","title":"沃森生物(300142)披露召开2026年第三次临时股东会通知,7月23日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653268057","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653268057?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:06","pubTimestamp":1784815585,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘,沃森生物报收于13.26元,较前一交易日下跌1.7%,最新总市值为212.07亿元。该股当日开盘13.35元,最高13.53元,最低13.01元,成交额达8.72亿元,换手率为4.17%。近日,沃森生物发布《关于召开2026年第三次临时股东会的通知》。公告显示,公司将于2026年8月12日召开2026年第三次临时股东会,会议由董事会召集,现场会议地点为公司会议室。股权登记日为2026年8月5日。公司将对中小投资者表决单独计票并披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300047821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0046","BK0077","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653874265","title":"沃森生物最新公告:子公司双价HPV疫苗获坦桑尼亚药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2653874265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653874265?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:30","pubTimestamp":1784806232,"startTime":"0","endTime":"0","summary":"沃森生物(300142.SZ)公告称,公司子公司玉溪泽润生产的双价HPV疫苗(商品名“WALRINVAX”)近日获得坦桑尼亚药品和医疗器械管理局签发的《药品注册证书》,获批上市许可。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300042512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","BK0046","BK0070","BK0077","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653713626","title":"沃森生物:公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2653713626","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653713626?lang=zh_cn&edition=full","pubTime":"2026-07-23 11:43","pubTimestamp":1784778232,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月22日在投资者关系平台上答复投资者关心的问题。公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中。公司密切关注相关法规和政策的调整变化情况,将严格按照相关法规和规范性文件的规定审慎推进项目工作并披露项目进展信息。本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300019990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399300","BK0070","BK0077","300142","BK0239","159982","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653616713","title":"沃森生物:公司目前经营情况正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2653616713","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653616713?lang=zh_cn&edition=full","pubTime":"2026-07-23 11:43","pubTimestamp":1784778231,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月22日在投资者关系平台上答复投资者关心的问题。公司严格按照《深圳证券交易所创业板股票上市规则》等法律法规的要求履行信息披露义务。关于半年度业绩预告,公司会依据监管规则及自身实际情况进行综合评估。公司半年度报告预约披露时间在创业板允许的期限内,公司目前经营情况正常,具体业绩数据请以公司后续在巨潮资讯网披露的《2026年半年度报告》为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300019982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0046","BK0239","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653564224","title":"沃森生物:截至4月底已收回玉溪沃森全部股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2653564224","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653564224?lang=zh_cn&edition=full","pubTime":"2026-07-21 15:06","pubTimestamp":1784617581,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月21日在投资者关系平台上答复投资者关心的问题。玉溪沃森为公司的核心子公司,截至4月底,公司已收回了玉溪沃森的全部股权,玉溪沃森已成为公司全资子公司。目前已进入公司半年报编制期间,相关数据和信息在持续汇总和校验中,玉溪沃森的营收、利润等经营数据将并入公司定期报告合并财务报表数据,相关信息请以公司披露的定期报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100022848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0046","BK0070","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653224894","title":"沃森生物:持续推进新冠变异株mRNA疫苗研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2653224894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653224894?lang=zh_cn&edition=full","pubTime":"2026-07-21 15:03","pubTimestamp":1784617392,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月21日在投资者关系平台上答复投资者关心的问题。公司严格按照国家药品注册程序的有关规定持续推进新型冠状病毒变异株mRNA疫苗、新型冠状病毒变异株mRNA疫苗及其迭代疫苗新型冠状病毒变异株mRNA疫苗的研发和申报工作,关于公司在研产品的进展信息请以公司披露的公告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100022824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0046","BK0239","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652293241","title":"公司问答丨沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2652293241","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652293241?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:54","pubTimestamp":1784534073,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0046","BK0239","BK0077","159646","BK0070","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298586","title":"沃森生物:爱森泽生物技术(昆明)有限公司作为公司光生物合成技术与产业化的平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652298586?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:03","pubTimestamp":1784530991,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月20日在投资者关系平台上答复投资者关心的问题。爱森泽生物技术(昆明)有限公司作为公司光生物合成技术与产业化的平台,与云南沃嘉一样,均属于公司合并财务报表范围内的子公司,其营收、利润等经营数据将并入公司定期报告财务数据,相关信息请以公司披露的定期报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000016975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0077","BK0070","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298585","title":"沃森生物:2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298585","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652298585?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:03","pubTimestamp":1784530991,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月20日在投资者关系平台上答复投资者关心的问题。公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中,本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施,关于项目的相关信息请以公司披露的公告为准。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000016974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","159982","BK0046","BK0077","399300","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652129830","title":"沃森生物:公司严格按照《企业会计准则》及公司具体会计政策界定疫苗研发支出的资本化与费用化时点","url":"https://stock-news.laohu8.com/highlight/detail?id=2652129830","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652129830?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:03","pubTimestamp":1784530990,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)07月20日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司疫苗研发支出资本化与费用化的划分时点如何界定?沃森生物回复:尊敬的投资者,您好!公司严格按照《企业会计准则》及公司具体会计政策界定疫苗研发支出的资本化与费用化时点。公司已根据自身业务特点制定了清晰的划分原则,具体时点的界定及会计处理政策,请您参见公司在巨潮资讯网披露的《2025年年度报告》“第八节 财务报告”之“五、重要会计政策及会计估计”中的“29、无形资产”部分的内容。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000016973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0046","300142","BK0239","159646","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651185204","title":"沃森生物:冻干带状疱疹mRNA疫苗于2025年12月获得《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2651185204","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651185204?lang=zh_cn&edition=full","pubTime":"2026-07-16 11:37","pubTimestamp":1784173054,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月16日在投资者关系平台上答复投资者关心的问题。2026年上半年有无新增海外市场准入或大额订单?关于公司经营性现金流等相关财务数据、产品海外销售情况、国际市场拓展情况等的相关信息请以公司披露的定期报告为准。公司冻干带状疱疹mRNA疫苗于2025年12月获得《药物临床试验批准通知书》,关于该疫苗的后续进展情况请持续关注公司披露的公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600015423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0070","BK0046","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651480910","title":"沃森生物:九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2651480910","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651480910?lang=zh_cn&edition=full","pubTime":"2026-07-15 08:48","pubTimestamp":1784076491,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问:九价HPV疫苗:公司九价HPV疫苗目前III期临床具体进展如何?是否已按CDE要求完成全部受试者入组,预计何时提交上市申请(NDA)?沃森生物回复:尊敬的投资者,您好!公司九价HPV疫苗目前处于III期临床研究阶段,公司将按照国家对于疫苗注册临床试验的有关程序和要求推进相关工作。关于产品的后续进展情况请持续关注公司披露的信息。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500009804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0046","159646","BK0070","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650190963","title":"沃森生物:2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2650190963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650190963?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:36","pubTimestamp":1783654575,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问:投资者普遍关注,公司定增方案早已通过董事会审议,为什么时至今日,依然没有提交交易所审批?沃森生物回复:尊敬的投资者,您好!公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中,本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施。公司始终严格按照相关法规和规范性文件的规定披露项目进展信息,后续进展情况还请持续关注公司披露的公告。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000016471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","399300","BK0077","159982","BK0070","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650096739","title":"沃森生物:爱森泽生物聚焦医药健康天然产物的光生物合成","url":"https://stock-news.laohu8.com/highlight/detail?id=2650096739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650096739?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:36","pubTimestamp":1783654575,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月09日在投资者关系平台上答复投资者关心的问题。请问沃森生物目前在合成生物学布局的技术与产物,是否具备向半导体设备及材料领域延伸的技术基础?爱森泽生物技术(昆明)有限公司作为公司光生物合成技术与产业化的平台,聚焦于医药健康天然产物的光生物合成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000016470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","300142","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650909541","title":"沃森生物:公司严格遵守相关法律法规,不存在违规行为","url":"https://stock-news.laohu8.com/highlight/detail?id=2650909541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650909541?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:34","pubTimestamp":1783654440,"startTime":"0","endTime":"0","summary":"公司严格遵守《证券法》《上市公司信息披露管理办法》及非公开发行股票相关法律法规,合规经营,不存在投资者所提及的违规行为。公司董事会及管理层将持续关注公司价值表现,依法合规地维护全体股东特别是中小股东的合法权益,感谢您的关注与理解。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000016300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","300142","BK0046","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650096689","title":"沃森生物:共有8个疫苗产品正式上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2650096689","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650096689?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:33","pubTimestamp":1783654421,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月09日在投资者关系平台上答复投资者关心的问题。目前,公司共有8个疫苗产品正式上市销售,覆盖肺炎、脑膜炎、HPV、百白破及b型流感嗜血杆菌等预防领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000016264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","300142","BK0070","BK0239","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649348619","title":"股市必读:沃森生物(300142)7月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2649348619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649348619?lang=zh_cn&edition=full","pubTime":"2026-07-06 03:32","pubTimestamp":1783279934,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,沃森生物报收于13.2元,上涨1.62%,换手率4.28%,成交量67.52万手,成交额8.86亿元。董秘最新回复投资者: 公司定增方案是否已报国家有关单位审批?公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中,本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施。当日关注点交易信息汇总:7月3日沃森生物主力资金净流入314.59万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600001231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","BK0046","BK0239","300142"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785443667133,"stockEarnings":[{"period":"1week","weight":-0.0814},{"period":"1month","weight":-0.0624},{"period":"3month","weight":-0.0536},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0371},{"period":"ytd","weight":0.1306}],"compareEarnings":[{"period":"1week","weight":-0.0186},{"period":"1month","weight":-0.0708},{"period":"3month","weight":-0.0748},{"period":"6month","weight":-0.0761},{"period":"1year","weight":0.0523},{"period":"ytd","weight":-0.0414}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"118448人(较上一季度减少0.27%)","perCapita":"13313股","listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","registeredCapital":"159934万元","survey":" 云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业,也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。","listedPrice":95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沃森生物,300142,沃森生物股票,沃森生物股票老虎,沃森生物股票老虎国际,沃森生物行情,沃森生物股票行情,沃森生物股价,沃森生物股市,沃森生物股票价格,沃森生物股票交易,沃森生物股票购买,沃森生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}